VSIG IgG Superfamily Members: Data Supports Their Potential as Immunotherapeutic Drug Targets

The B7 family and other T cell co-stimulatory/co-inhibitory molecules are widely recognized as therapeutic targets for cancer immunotherapy. Many of these are members of the large immunoglobulin superfamily. V-Set and Immunoglobulin domain containing (VSIG) proteins are members of the immunoglobulin protein superfamily and are increasingly recognized as potential immuno-oncology targets. Perhaps the best-known member, VSIG9/TIGIT, has T cell and NK cell inhibitory function, while VSIG4 can negatively regulate T cell proliferation and IL-2 production. Our own unpublished observations reveal that other VSIG proteins also negatively regulate T cell function (see data below).

R&D Systems exclusively offers bioactive VSIG proteins in both unlabeled and biotinylated formats for identifying binding partners and the development of novel therapies for immune checkpoint blockade.

VSIG3-induced Immunosuppression. Recombinant Human VSIG3 Fc Chimera (Catalog # 9229-VS) inhibits anti-CD3 antibody induced IL-17 secretion in human PBMCs. The ED₅₀ for this effect is 1-6 ug/mL.

VSIG10L-induced Immunosuppression. Recombinant Human VSIG-10L Fc Chimera (Catalog # 9600-VS) inhibits IFN-gamma
secretion by human peripheral blood
mononuclear cells in the presence of anti-CD3 antibody. The ED₅₀ for this effect is 1-6 µg/mL.

Biotinylated and Unlabeled VSIG8 Suppress IL-2 Secretion. Recombinant Human VSIG-8 Fc Chimera (Catalog # 9200-VS) inhibits IL-2 secretion by human T cells in the presence of anti-CD3 antibody. The ED₅₀ for this effect is 1-5 μg/mL. Highlighting its specificity, Biotinylated Recombinant Human VSIG-8 Fc (Catalog # BT9200; Coming Soon) exhibits similar activity.

Bioactive Recombinant VSIG Proteins Available from R&D Systems